8 completed, 8 recruiting, 5 unknown, 3 terminated. 26 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 8, Recruiting 8, Unknown 5, Terminated 3, Suspended 1, Withdrawn 1 |
| Phase 2 | 14 | Completed 6, Recruiting 4, Unknown 2, Terminated 1, Withdrawn 1 |
Follow Cardiomyopathy, Dilated: new trials by email Literature Review of Cardiomyopathy, Dilated trials Research Report on Cardiomyopathy, Dilated
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM) AFTX-201 - Dilated Cardiomyopathy (DCM), BAG3 Mutation Associated Dilated Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | Affinia Therapeutics | 22 | 2026-12-01 | 2026-11-03 |
| A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA) NVC-001 - Low Dose, NVC-001 - Intermediate Dose, NVC-001 - High Dose - LMNA-Related Dilated Cardiomyopathy | Phase 1 / Phase 2 | Recruiting | Nuevocor Pte. Ltd. | 21 | 2026-06-16 | 2026-08-07 |
| Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy FAP immunosuppressive CAR-DC - Dilated Cardiomyopathy (DCM), Heart Failure | Phase 1 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 5 | 2026-05-11 | 2026-07-02 |
| A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3) - Dilated Cardiomyopathy (DCM) | Phase 1 | Recruiting | Rocket Pharmaceuticals Inc. | 8 | 2026-04-17 | 2026-10-01 |
| Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study) HS-005 - Heart Failure, Ischemic Heart Failure | Phase 1 / Phase 2 | Recruiting | Heartseed Inc. | 14 | 2026-01-19 | 2026-10-22 |
| A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy AZD4063 - Dilated Cardiomyopathy | Phase 1 | Recruiting | AstraZeneca | 23 | 2025-12-01 | 2026-09-04 |
| A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM) Allogeneic Neonatal mesenchymal stromal cells (nMSCs) - Dilated Cardiomyopathy | Phase 1 | Recruiting | Emory University | 36 | 2025-07-14 | 2026-06-26 |
| Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy FAP immunosuppressive CAR-DC - Dilated Cardiomyopathy (DCM), Heart Failure | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 43 | 2025-04-22 | 2026-07-14 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants. AZD0233, AZD0233 Placebo - Dilated Cardiomyopathy | Phase 1 | Terminated | AstraZeneca | 84 | 2024-04-01 | 2026-01-26 |
| Treating Congestive HF With hiPSC-CMs Through Endocardial Injection hiPSC-CM therapy - Cardiovascular Diseases, Congestive Heart Failure | Phase 1 | Unknown | HELP Therapeutics Co., Ltd. | 20 | 2021-09-21 | 2022-09-23 |
| v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 MYK-491, Placebo - Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 52 | 2018-02-06 | 2023-02-02 |
| Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy CDC infusion - Dilated Cardiomyopathy | Phase 1 | Completed | Okayama University | 5 | 2017-04-14 | 2021-11-26 |
| A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 MYK-491 or placebo - Dilated Cardiomyopathy | Phase 1 | Completed | MyoKardia, Inc. | 64 | 2017-01-16 | 2018-03-23 |
| Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) Allogeneic Cardiosphere-Derived Cells (CDCs) - Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy | Phase 1 | Unknown | Capricor Inc. | 42 | 2014-11-01 | 2016-06-21 |
| Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy bone marrow-derived MSCs injection, placebo intervention - Primary Idiopathic Dilated Cardiomyopathy | Phase 1 / Phase 2 | Unknown | Hospital General Universitario Gregorio Marañon | 70 | 2013-03-01 | 2016-11-18 |
| Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy ucMSC, Controls - Dilated Cardiomyopathy | Phase 1 / Phase 2 | Completed | Universidad de los Andes, Chile | 30 | 2012-12-01 | 2015-06-04 |
| Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy Intracoronary autologous stem cell infusion - Cardiomyopathy, Dilated | Phase 1 | Suspended | Hospital Universitario Dr. Jose E. Gonzalez | 10 | 2012-01-01 | 2013-08-09 |
| PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study) Autologous hMSCs, Allogeneic hMSCs - Non-ischemic Dilated Cardiomyopathy | Phase 1 / Phase 2 | Completed | Joshua M Hare | 37 | 2011-05-19 | 2018-02-15 |
| Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy umbilical cord mesenchymal stem cells - Dilated Cardiomyopathy | Phase 1 / Phase 2 | Unknown | Qingdao University | 30 | 2010-10-01 | 2010-10-28 |
| Stem Cells and Resynchronization Cardiac Pacing and Stem Cells Implantations., Pacing and Stem Cells Implantation - Heart Failure | Phase 1 | Unknown | Instituto de Molestias Cardiovasculares | 30 | 2008-11-01 | 2011-06-23 |
Showing 20 of 26. Sign in to see all of them.
Heart Failure (16) · Cardiomyopathies (4) · Cardiovascular Diseases (4) · Heart Diseases (3) · Coronary Disease (1) · Dilatation, Pathologic (1) · Myocardial Ischemia (1) · Pathologic Processes (1) · Ventricular Dysfunction (1)
Cardiomegaly (26) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Genetic Diseases, Inborn (26) · Laminopathies (26) · Heart Diseases (23) · Cardiomyopathies (22) · Cardiovascular Diseases (22) · Pathological Conditions, Signs and Symptoms (2) · Vascular Diseases (2) · Myocardial Ischemia (1) · Pathological Conditions, Anatomical (1)
Allopurinol (1) · Cardiac Resynchronization Therapy (1) · Clenbuterol (1) · Dobutamine (1)
AstraZeneca (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Affinia Therapeutics (1) · Bristol-Myers Squibb (1) · Capricor Inc. (1) · Celladon Corporation (1) · Emory University (1) · Francis D. Pagani (1) · HELP Therapeutics Co., Ltd. (1) · Heartseed Inc. (1) · Henry M. Spotnitz (1) · Hospital General Universitario Gregorio Marañon (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Instituto de Cardiologia do Rio Grande do Sul (1) · Instituto de Molestias Cardiovasculares (1)
United States (12) · China (4) · Brazil (2) · Japan (2) · Netherlands (2) · Australia (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Mexico (1) · Poland (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Xinyang Hu, PhD (2) · A. G. Kfoury, MD (1) · Andreas M Zeiher (1) · Andrew Kao, MD (1) · Barry Greenberg, MD (1) · Barry London, MD (1) · Brian Jaski, MD (1) · Consuelo Mancias, Hematologist (1) · Daniel Pauly, MD (1) · Deborah Ascheim, MD (1) · Dinesh K. Gupta, MD (1) · Donna Mancini, MD (1) · Douglas W. Losordo, MD (1) · Eric J. Eichhorn, MD, FACC (1) · Francis D. Pagani, MD, PhD (1)
PMID 17874006, PMID 18553028, PMID 19327618, PMID 21709064, PMID 22651868, PMID 22936827, PMID 23362308, PMID 24065463, PMID 25354998, PMID 28974553, PMID 30005555, PMID 31616309, PMID 33298561
2025 (1), K23HL071562 (1), R01HL080152 (1), R01HL110737 (1), R44HL095203 (1)